(Q45616224)

English

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

scientific article published in July 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Cosette M Wheeler

2

object named as

Cosette M Wheeler

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

8

object named as

Kathrin U Jansen

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

7

object named as

Nancy B Kiviat

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

3

object named as

Laura A Koutsky

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Kenneth H Fife

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Eliav Barr

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Darron R Brown

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Melissa A Schiff

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Harriet Barber

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Judith F Smith

10

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Amha Tadesse

11

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Katherine Giacoletti

12

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Paula R Smith

13

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Gretchen Suhr

14

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Daniel A Johnson

15

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

1 July 2004

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

21-22

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2943-2952

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Epidemiology of Genital Human Papillomavirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Genital warts and their treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Screening for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Benefits and costs of using HPV testing to screen for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Combined colposcopy, loop conization, and laser vaporization reduces recurrent abnormal cytology and residual disease in cervical dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Partial characterization of viral DNA from human genital warts (condylomata acuminata)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Testing the statistical certainty of a response to increasing doses of a drug

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Antibody-Mediated Neutralization of Human Papillomavirus Type 11 (HPV-11) Infection in the Nude Mouse: Detection of HPV-11 mRNAs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular cloning of viral DNA from human genital warts.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.058

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2003.11.058

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45616224&oldid=2077436938"